Buy Votrient : Pazopanib 400 Mg Tablets 30’S Online

Description

Votrient, manufactured by GlaxoSmithKline (GSK) Pharmaceuticals Ltd., stands at the forefront of targeted cancer therapy, offering a beacon of hope for individuals battling advanced or metastatic cancers. Each pack of Votrient contains 30 tablets, with each tablet containing 400 mg of Pazopanib, the active ingredient.

Key Features:

1. Multi-Targeted Kinase Inhibitor: Votrient contains Pazopanib, a potent multi-targeted tyrosine kinase inhibitor (TKI) that selectively targets and inhibits the activity of multiple receptor tyrosine kinases (RTKs) involved in tumor growth, angiogenesis, and metastasis. By interfering with these signaling pathways, Pazopanib effectively suppresses cancer cell proliferation and tumor progression.
2. Broad Spectrum of Activity: Votrient demonstrates efficacy against a variety of cancers, including renal cell carcinoma (RCC), soft tissue sarcoma (STS), and ovarian cancer. Its broad spectrum of activity makes it a valuable treatment option for patients with advanced or metastatic cancer who have exhausted other therapeutic options.
3. Anti-Angiogenic Effects: Pazopanib exerts potent anti-angiogenic effects by inhibiting vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs), key regulators of tumor angiogenesis. By disrupting tumor blood supply and inhibiting the formation of new blood vessels, Pazopanib helps deprive tumors of oxygen and nutrients, ultimately leading to tumor regression.
4. Oral Administration: Votrient is available in convenient oral tablet form, allowing for easy administration and patient compliance. The once-daily dosing regimen offers flexibility and convenience for patients undergoing long-term cancer treatment.
5. Well-Tolerated: While targeted therapy drugs may be associated with side effects, Votrient is generally well-tolerated when used as prescribed under the supervision of a qualified healthcare professional. Common side effects may include fatigue, diarrhea, hypertension, nausea, vomiting, and decreased appetite. Most side effects are manageable and reversible with appropriate medical management.

Usage Guidelines:

• Votrient should be taken orally with a full glass of water, preferably on an empty stomach, at least one hour before or two hours after a meal.
• The recommended dosage of Votrient is 800 mg (two tablets of 400 mg each) once daily. Dosage adjustments may be made based on individual patient response and tolerability.
• Regular monitoring of blood pressure, liver function, and thyroid function is essential during treatment with Votrient to detect and manage any potential adverse effects or complications.

Votrient (Pazopanib 400 Mg Tablets) is a prescription medication indicated for the treatment of various types of advanced or metastatic cancers. It should only be used under the guidance and supervision of a qualified healthcare professional experienced in the management of cancer patients. The decision to initiate treatment with Votrient should be based on thorough clinical evaluation and consideration of individual patient factors.